Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)

NCT00365378 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

2409

Enrollment

INDUSTRY

Sponsor class

Conditions

HPV 16 Infection

Interventions

BIOLOGICAL: Comparator: HPV 16 L1 Vaccine
BIOLOGICAL: Comparator: Placebo

Sponsor

Merck Sharp & Dohme LLC